IACP Submits Comments for FDA's
Review of Existing Center for Drug Evaluation and Research Regulatory and Information Collection Requirements
The International Academy of Compounding Pharmacists (IACP) has submitted comments to the Food & Drug Administration (FDA) for its Docket No.: FDA-2017-N-5101 for "Review of Existing Center for Drug Evaluation and Research Regulatory and Information Collection Requirements."
View IACP's Comments Submitted to FDA:
Please click here to view IACP's complete comments on the
Guidance for Industry: Prescription Requirement Under 503A of the Food, Drug and Cosmetic Act.
Please click here to view IACP's complete comments on the
Draft Standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products Between the States and the Food and Drug Administration.
Make Sure Your Patients' Voices are Heard - Submit Your Comments!
Comment submission instructions and FDA Docket Number are provided
here to assist you in submitting comments!
Please note: FDA's comment submission deadline is Monday, February 5, 2018.
IACP MEMBERS: You are welcome and encouraged to use IACP's comments in your own submissions to FDA.
How to Submit Comments:
Submit Comments:
Please note comments are due Monday, February 5, 2018. The docket number is FDA-2017-N-5101. The docket will close on February 5, 2018.
Please click here to visit FDA's document submission site. Both written and electronic submission instructions are provided.
It's important that we make our voices heard on behalf of our patients!
Patient access to compounded medications
is a patient safety issue.
|